<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01585753</url>
  </required_header>
  <id_info>
    <org_study_id>MARCH-Kirby VE substudy</org_study_id>
    <nct_id>NCT01585753</nct_id>
  </id_info>
  <brief_title>MARCH Vascular Endothelium Substudy</brief_title>
  <acronym>MARCH VE</acronym>
  <official_title>Maraviroc Switch Vascular Endothelium (VE) Substudy: a Substudy of MARCH</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kirby Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kirby Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a substudy of MARCH, in which we are exploring the changes in the vascular
      endothelium using pulse wave tonometry (a non invasive measure of cardiac health) to measure
      the changes in small and large arterial elasticity in participants of the MARCH study who
      switch to maraviroc-based regimens over 96 weeks of follow-up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiovascular disease is increasingly recognised as a complication of HIV +/- therapies to
      treat it. Blood vessel elasticity, or compliance, can be depicted as the ability of the
      vessels to convert intermittent blood flow (cardiac ejection during systole) to continuous
      blood flow throughout the cardiac cycle. The compliance, or ability of vessels to accept
      energy, can be subdivided into elasticity of large and small vessels. Pulse wave tonometry is
      a non-invasive technique performed using a hand-held tonometer that generates two indices
      which correspond to large artery elasticity (LAE) and small artery elasticity (SAE). LAE and
      SAE estimates by pulse waveform analysis have previously shown greater correlation to
      Framingham risk when directly compared with other techniques such as flow-mediated diltation,
      and both LAE and SAE are associated with traditional cardiovascular risk factors (smoking,
      insulin resistance, hypertension).

      It is unclear what the net effect of maraviroc, a chemokine-receptor blocker is on
      cardiovascular function.

      The aims of this substudy are:

        -  To compare changes in the vascular endothelium between the control arm ((N(t)RTI) plus
           PI/r) and each of the maraviroc switch arms over 48 weeks of follow-up.

        -  To compare the changes in biomarkers and selected immunological markers between the
           control arm ((N(t)RTI) plus PI/r) and each of the maraviroc switch arms over 48 weeks of
           follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in small arterial elasticity (SAE) as measure by pulse wave tonometry</measure>
    <time_frame>96 weeks</time_frame>
    <description>measured at 6 timepoints week 0, 4, 12, 24, 48, 96</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Mean change in large arterial elasticity (LAE) as measure by pulse wave tonometry</measure>
    <time_frame>96 weeks</time_frame>
    <description>measured at 6 timepoints, week 0,4,12,24,48,96</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Changes from baseline in selected soluble markers of immune activation, coagulation, vascular and platelet function</measure>
    <time_frame>96 weeks</time_frame>
    <description>stored bloods from the main study will be used to explore changes in vascular biomarkers</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">34</enrollment>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <description>NRTI and PI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <description>Maraviroc + PI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <description>maraviroc + NRTI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NRTI + PI</intervention_name>
    <description>tenofovir zidovudine abacavir lamivudine emtricitabine ritonavir darunavir atazanavir lopinavir fosamprenavir</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>maraviroc + PI</intervention_name>
    <description>maraviroc ritonavir darunavir atazanavir lopinavir fosamprenavir</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>maraviroc + NRTI</intervention_name>
    <description>maraviroc tenofovir zidovudine abacavir lamivudine emtricitabine</description>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants in MARCH
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Enrolled prior to treatment in the parent study;

          -  Provision of written, informed consent for participation in the substudy

        Exclusion Criteria:

          -  Known supraventricular tachycardia such as atrial flutter and/or fibrillation that
             precludes the measurement of pulse wave using tonometry.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah L Pett, FRACP,FRCPE,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kirby Institute, UNSW</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital General de Agudos &quot;Dr. José María Ramos Mejía&quot;</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1221ADC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion IDEAA</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1405CKC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano de Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johann Wolfgang Goethe-University Hospital, Medical HIVCENTER</name>
      <address>
        <city>Frankfurt</city>
        <state>Frankfurt am Main</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chulalongkorn University Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Germany</country>
    <country>Thailand</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2012</study_first_submitted>
  <study_first_submitted_qc>April 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2012</study_first_posted>
  <last_update_submitted>January 18, 2016</last_update_submitted>
  <last_update_submitted_qc>January 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cardiovascular function</keyword>
  <keyword>maraviroc</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maraviroc</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

